Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro

Fertility and Sterility

Volumn 93, Issue 6, 2010, Pages 2042-2047

  Shah, Divya K ^a   Menon, K M J ^a   Cabrera, Lourdes M ^a   Vahratian, Anjel ^a   Kavoussi, Shahryar K ^a   Lebovic, Dan I ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

granulosa cells; OHSS; PPAR gamma; Thiazolidinediones; VEGF

Indexed keywords

CHORIONIC GONADOTROPIN; CIGLITAZONE; DIMETHYL SULFOXIDE; PIOGLITAZONE; RECOMBINANT FOLLITROPIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BLASTOCYST; CELL PROLIFERATION; CELL STRUCTURE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EMBRYO; EXPERIMENTAL STUDY; FEMALE; GRANULOSA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPEROVULATION; ZYGOTE;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO CULTURE TECHNIQUES; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; GRANULOSA CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LUTEINIZATION; MALE; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949918850     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.059     Document Type: Article

References (34)

1. Kaczmarek M.M., Schams D., and Ziecik A.J. Role of vascular endothelial growth factor in ovarian physiology-an overview. Reprod Biol 5 (2005) 111-137
2. Rizk B., Aboulghar M., Smitz J., and Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3 (1997) 255-266
3. Lee A., Christenson L.K., Patton P.E., Burry K.A., and Stouffer R.L. Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. Hum Reprod 12 (1997) 2756-2761
4. Kamat B.R., Brown L.F., Manseau E.J., Senger D.R., and Dvorak H.F. Expression of VPF/VEGF by human granulosa and theca lutein cells: role in corpus luteum development. Am J Pathol 146 (1995) 157-165
5. Zimmermann R.C., Hartman T., Kavic S., Pauli S.A., Bohlen P., Sauer M.V., et al. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J Clin Invest 112 (2003) 659-669
6. Manau D., Fábregues F., Peñarrubia J., Creus M., Carmona F., Casals G., et al. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Hum Reprod 3 (2007) 669-675
7. Agrawal R., Conway G., Sladkevicius P., Tan S.L., Engmann L., Payne N., et al. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 71 (1998) 287-293
8. Lemberger T., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12 (1996) 335-363
9. Froment P., Gizard F., Defever D., Staels B., Dupont J., and Monget P. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol 189 (2006) 199-209
10. Komar C.M. Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol 3 (2005) 41
11. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., et al. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110 (2002) 923-932
12. Peeters L.L.H., Vigne J., Tee M.K., Zhao D., Waite L.L., and Taylor R.L. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 8 (2005) 373-379
13. Nair A.K., Peegal H., and Menon K.M.J. The role of luteinizing hormone/human chorionic gonadotropin receptor-specific mRNA binding protein in regulating receptor expression human ovarian granulosa cells. J Clin Endocrinol Metabol 91 (2006) 2239-2243
14. Asimakopoulos B., Nkolettos N., Nehls B., Diedrich K., Al-Hasani S., and Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 86 (2006) 636-641
15. Ferry G., Bruneau V., Beauverger P., Goussard M., Rodriguez M., Lamamy V., et al. Binding of prostaglandins to human PPARγ: tool assessment and new natural ligands. Eur J Pharmacol 417 (2001) 77-89
16. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferators-activated receptor-γ ligands are potent inhibitors of angiogenesisin vitroand in vivo. J Biol Chem 274 (1999) 9916-9921
17. McClure N., Healy D.L., Rogers P.A.W., Sullivan J., Beaton L., Haning R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 (1994) 235-236
18. Gómez R., Simón C., Remohi J., and Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rates, and this effect is prevented by receptor blockage. Endocrinology 143 (2002) 4339-4348
19. Koos R.D., and Olson C.E. Hypoxia stimulates expression of the gene for vascular endothelial growth factor (VEGF), a putative angiogenic factor, by granulosa cells of the ovarian follicle, a site of angiogenesis. J Cell Biol 115 (1991) 421a
20. Yamamoto S., Konishi I., Tsuruta Y., Nanbu K., Mandai M., Kuroda H., et al. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 11 (1997) 371-381
21. Neulen J., Yan Z., Raczek S., Weindel K., Keck C., Weich H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80 (1995) 1967-1971
22. Kosaka K., Fujiwara H., Yoshioka S., and Fujii S. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22 (2007) 1647-1651
23. Villasante A., Pacheco A., Pau E., Ruiz A., Pellicer A., and García-Velasco J.A. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 23 (2008) 662-667
24. Soares S.R., Gómez R., Simón C., García-Velasco J.A., and Pellicer A. Targeting the vascular endoethelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14 (2008) 321-333
25. Manno M., Tomei F., Marchesan E., and Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 122 (2005) 127-128
26. Gómez R., Gonzalez-Izquierdo M., Zimmerman R.C., Novella-Maestre E., Alonso-Muriel I., Sanchez-Criado J., et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEG-F)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent lutueal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147 (2006) 5400-5411
27. Alvarez C., Martii-Bonmati L., Novella-Maestre E., Sanz R., Gomez R., Fernandez-Sanchez M., et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92 (2007) 2931-2937
28. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
29. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular evenets in patients with type 2 diabetes mellitus. JAMA 298 (2007) 1180-1188
30. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 (2002) S23-S29
31. Van Gaal L., and Scheen A.J. Are all glitazones the same?. Diabetes Metab Res Rev 18 (2002) S1-S4
32. Klinker D.B., Lim H.J., Strawn E.Y., Oldham K.T., and Sander T.L. An in vivo murine model of rosiglitazone use in pregnancy. Fertil Steril 86 (2006) 1074-1079
33. Minge C.E., Bennett B.D., Norman R.J., and Robker R.L. Peroxisome proliferators-activated receptor-γ agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality. Endocrinology 149 (2008) 2646-2656
34. Haddad G.F., Jodicke C., Thomas M.A., Williams D.B., and Aubuchon M. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 26 (2008) 183-184